Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

× No keyword cloud information.

13 in total

1. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.

Authors: Santhanam Sundar; Peter D Dickinson
Journal: BMJ Case Rep Date: 2012-02-25

2. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.

Authors: Scott T Tagawa; Himisha Beltran
Journal: Asian J Androl Date: 2011-08-22 Impact factor: 3.285

Review 3. Corticosteroids in the management of prostate cancer: a critical review.

Authors: Chukwuma Ndibe; Christopher G Wang; Guru Sonpavde
Journal: Curr Treat Options Oncol Date: 2015-02

Review 4. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors: David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal: Nat Rev Urol Date: 2015-01 Impact factor: 14.432

5. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.

Authors: Karen E Knudsen; William Kevin Kelly
Journal: Expert Rev Endocrinol Metab Date: 2011-05

Review 6. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors: E S Antonarakis; A J Armstrong
Journal: Prostate Cancer Prostatic Dis Date: 2011-05-17 Impact factor: 5.554

7. Abiraterone and increased survival in metastatic prostate cancer.

Authors: Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245

Review 8. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.

Authors: James L Gulley; Charles G Drake
Journal: Clin Cancer Res Date: 2011-06-15 Impact factor: 12.531

Review 9. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.

Authors: Gerhardt Attard; Juliet Richards; Johann S de Bono
Journal: Clin Cancer Res Date: 2011-03-03 Impact factor: 12.531

10. A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.

Authors: Ravinder Clayton; Jackson Wu; Daniel Y Heng; Scott A North; Urban Emmenegger; Sebastien Hotte; Kim Chi; Rob Zielinski; Humaid Al-Shamsi; Leo Chen; Bernhard Eigl
Journal: Can Urol Assoc J Date: 2014-09 Impact factor: 1.862